Hovid Berhad is another example of Malaysia's healthcare biotechnology success story. Starting out as a single product company in 1945, Hovid today has 12 global patents and a presence in 40 countries worldwide. The company set up another unit, Carotech Bhd. which commenced production in 1995 and has since successfully carved a niche to become a leading supplier of phytonutrients throughout the world, with the US, Europe, Japan and Australia making up the main markets. In January 2008, Hovid bought a controlling stake in Biodeal Pharmaceuticals. For the financial year ended June 30 last year, the company recorded RM214.7 million revenue and RM15.3 million net profit.
Frost & Sullivan is proud to partner with BiotechCorp in this Investor Series in Sydney to showcase the investment opportunities in the Malaysian Biotechnology sector within the context of the global market to potential investors and other interested parties. The event will highlight the strengths of the sector in the fields of Healthcare, Industrial and Agriculture Biotechnology.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact: Jasminder Kaur Corporate Communications -Healthcare, Asi
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved